

UCLA

UCLA Previously Published Works

Title

Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state

Permalink

<https://escholarship.org/uc/item/79w989vb>

Journal

Substance Abuse Treatment, Prevention, and Policy, 17(1)

ISSN

1747-597X

Authors

Padwa, Howard
Huang, David
Mooney, Larissa
[et al.](#)

Publication Date

2022

DOI

10.1186/s13011-022-00467-1


Peer reviewed

RESEARCH

Open Access



Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state

Howard Padwa^{1*} , David Huang¹, Larissa Mooney¹, Christine E. Grella¹, Darren Urada¹, Douglas S. Bell^{2,3}, Brittany Bass¹ and Anne E. Boustead⁴

Abstract

Background: Approximately 3.8% of adults worldwide have used cannabis in the past year. Understanding how cannabis use is associated with other health conditions is crucial for healthcare providers seeking to understand the needs of their patients, and for health policymakers. This paper analyzes the relationship between documented cannabis use disorders (CUD), cannabis use (CU) and other health diagnoses among primary care patients during a time when medical use of marijuana was permitted by state law in California, United States of America.

Methods: The study utilized primary care electronic health record (EHR) data from an academic health system, using a case–control design to compare diagnoses among individuals with CUD/CU to those of matched controls, and those of individuals with CUD diagnoses with individuals who had CU otherwise documented. Associations of documented CU and CUD with general medical conditions and health conditions associated with cannabis use (both medical and behavioral) were analyzed using conditional logistic regression.

Results: Of 1,047,463 patients with ambulatory encounters from 2013–2017, 729 (0.06%) had CUD diagnoses and 3,731 (0.36%) had CU documented in their EHR. Patients with documented CUD and CU patients had significantly ($p < 0.01$) higher odds of most medical and behavioral diagnoses analyzed. Compared to matched controls, CUD-documented patients had highest odds of other substance use disorders (OR = 21.44; 95% CI 9.43–48.73), any mental health disorder (OR = 6.99; 95% CI 5.03–9.70) social anxiety disorder (OR = 13.03; 95% CI 2.18–77.94), HIV/AIDS (OR = 7.88; 95% CI 2.58–24.08), post-traumatic stress disorder (OR = 7.74; 95% CI 2.66–22.51); depression (OR = 7.01; 95% CI 4.79–10.27), and bipolar disorder (OR = 6.49; 95% CI 2.90–14.52). Compared to matched controls, CU-documented patients had highest odds of other substance use disorders (OR = 3.64; 95% CI 2.53–5.25) and post-traumatic stress disorder (OR = 3.41; 95% CI 2.53–5.25). CUD-documented patients were significantly more likely than

*Correspondence: hpadwa@mednet.ucla.edu

¹ Department of Psychiatry and Biobehavioral Sciences, University of California, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

CU-documented patients to have HIV/AIDS (OR = 6.70; 95% CI 2.10–21.39), other substance use disorder (OR = 5.88; 95% CI 2.42–14.22), depression (OR = 2.85; 95% CI 1.90–4.26), and anxiety (OR = 2.19; 95% CI 1.57–3.05) diagnoses.

Conclusion: The prevalence of CUD and CU notation in EHR data from an academic health system was low, highlighting the need for improved screening in primary care. CUD and CU documentation were associated with increased risk for many health conditions, with the most elevated risk for behavioral health disorders and HIV/AIDS (among CUD-documented, but not CU-documented patients). Given the strong associations of CUD and CU documentation with health problems, it is important for healthcare providers to be prepared to identify CU and CUD, discuss the pros and cons of cannabis use with patients thoughtfully and empathically, and address cannabis-related comorbidities among these patients.

Keywords: Cannabis, Comorbidities, Primary Care, Co-occurring disorders, Cannabis legalization

Background

Cannabis is the most widely used psychoactive substance after alcohol and tobacco, with approximately 3.8% of the world's adult population having used the drug in the past year [1]. The perceived harms associated with cannabis are decreasing [2, 3] while belief in its potential health benefits is increasing [3–5] and countries across the world are beginning to legalize cannabis for medical and/or non-medical use [6]. These trends make it likely that cannabis use will become increasingly common in the future [2, 7, 8]. Cannabis can have serious impacts on health [9–14], and patients often use the drug instead of other prescription medications to manage their health [13]. The purpose of this paper is to better understand the relationship between cannabis use, as documented in electronic health records (EHR), and other health diagnoses among primary care patients in a time when state law allowed for medical cannabis use, but not non-medical cannabis use.

Understanding the associations between cannabis use, medical conditions, and behavioral health can equip practitioners to more effectively identify patients who use cannabis and address the possible impacts the drug may have on their health. Currently, little is known about how often cannabis use is identified among primary care patients in health systems, or the degree to which it is associated with medical and psychiatric diagnoses among primary care populations. EHR data can be used to address these questions. For example, Campbell and colleagues [15] analyzed EHR data from community clinics in Oregon, California, and Washington State between 2012 and 2016, and found that primary care patients were more likely to have a cannabis use disorder (CUD), but not cannabis use without a disorder (CU), documented in EHRs if they had psychiatric diagnoses. Lapham and colleagues [16] analyzed data from a large integrated healthcare system in Washington State from 2015 to 2016, and found that mental health disorders, depression symptoms, tobacco use, unhealthy alcohol use, illicit drug use, and substance use disorders were

associated with increased cannabis use. Matson and colleagues [17] recently analyzed EHR data from a large integrated healthcare system in Washington State from 2017 to 2018 to measure the prevalence of documented medical cannabis use and its association with health conditions for which cannabis use could be potentially beneficial or harmful. They found that patients who had documented medical use of cannabis had higher prevalence of diagnoses for both conditions that could be adversely impacted or helped by cannabis use when compared to non-medical users and non-users [17].

Campbell and colleagues' data was collected from a mix of states that allowed for both medical (California at the time of data collection) and non-medical cannabis use (Oregon, Washington), while Matson and colleagues' data was collected only from Washington. To our knowledge, no published research has used EHR data to examine the prevalence of cannabis use or the association of cannabis with health diagnoses in places where cannabis is only legal for medical use. It is important to analyze data from samples in locations that have different cannabis policies because cannabis' legal status can influence who decides to use the drug, how frequently they use it, and the potency of the cannabis they consume [18–22]. Policy contexts also affect cannabis pricing, access, marketing, and social acceptability [23], which in turn can lead to differences in cannabis use and its consequences. The legal status of cannabis may influence patients' willingness to disclose their use to their physician when they seek treatment for a health problem leading to differences in how frequently it is documented in EHRs, and it can also impact the degree to which cannabis use may have negative social or legal consequences [5].

The goal of this paper is to complement the work of Campbell et al. [15] and Matson et al. [17] by analyzing EHR data from California between 2013 and 2017, when cannabis was only legal for medical use. As of May 2021, 18 states in the United States (U.S.) [24] and countries across the world—including the United Kingdom [25], Australia [26], and many nations in continental Europe

[27] and South America [28] — allowed for medical cannabis use, but not adult (non-medical) cannabis use. Findings from this study can be used to inform clinical practice in these places, and other jurisdictions that may allow medical cannabis use—but not non-medical cannabis use—in the future.

The paper has two aims: (1) to measure the prevalence of documented cannabis use disorder (CUD) and cannabis use (CU) in a large health system's EHR; and (2) to determine the odds that patients with documented CUD and CU had general co-occurring medical conditions and conditions known to be associated with cannabis use.

Methods

Study design

The study utilized EHR data from the Internal Medicine and Family Medicine departments of the University of California, Los Angeles Health System utilizing Epic/Clarity software. To determine the odds that individuals with CUD/CU documentation had specific health conditions, the study utilized a case-control design, comparing diagnoses among individuals with CUD/CU documentation to those of matched controls, and those of individuals with CUD diagnoses to those of individuals with documented CU.

Study sample

The study sample was drawn from 1,047,463 unique primary care patients aged 18 or older who had ambulatory care encounters documented in the health system EHR between January 1, 2013 and September 1, 2017. Sample patients had relatively high socio-economic status, as the median household income of health system patients' neighborhoods was over \$84,000, and over 64% of the patients had private insurance. Patients with CUD were identified with International Classification of Diseases, Tenth Revision (ICD-10) code F12 (cannabis-related disorders). Patients in the CU documentation group were identified by text searches of EHR social history notes, as has been done in other studies [15, 29]. Patients were considered part of the CU group if there was mention of "cannabis," misspelled variations of cannabis ("cannibis," "canbis," "canibis") or common colloquial equivalents ("marijuana," "pot," "weed," "grass") in EHR notes but there was no CUD diagnosis. In the event patients met both CUD and CU criteria, they were considered CUD patients. No exclusion criteria were used in the selection of case patients. Patient controls were identified and matched to the case patients by sex (male/female), race/ethnicity (White, Black, Hispanic, Asian/Pacific Islander, Other/Unknown), age (18–29, 30–39, 40–49, 50–59, 60–69, 70+), and first encounter year within the EHR system.

Measures

Diagnoses were identified by their International Classification of Diseases, Tenth Revision (ICD-10) codes in EHRs (see [Appendix](#) for the ICD-10 codes utilized). General co-occurring medical conditions examined included cancer, nervous system disease, circulatory system disease, respiratory disease, digestive system diseases, liver disease, diseases of the musculoskeletal system, HIV/AIDS, sexually transmitted diseases other than HIV/AIDS, mental health disorders, alcohol use disorders, tobacco use disorders, and substance use disorders other than those related to alcohol, cannabis, and tobacco.

Conditions known to be associated with cannabis were based on the National Academies of Sciences, Engineering and Medicine review of the health effects of cannabis and cannabinoids [13]. These conditions included cancer, respiratory disease, chronic obstructive pulmonary disease (COPD), ischemic heart disease (an indicator for myocardial infarction and ischemic stroke), obstructive sleep apnea, multiple sclerosis, Tourette Syndrome, testicular cancer, chronic pain, fibromyalgia, HIV/AIDS, schizophrenia/psychotic disorders, depression, anxiety, bipolar disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), alcohol use disorders, and other substance use disorders. See the [Appendix](#) for the ICD-10 codes used to identify these conditions.

Analyses

The odds that patients with CU or CUD documentation had had various physical, mental health, and substance use disorder diagnoses were calculated using conditional logistic regression models that utilized pairs (each with one case and one control) as strata. First, a simple conditional logistic regression model was applied to each health condition, in which the presence of each diagnosis was included as the dependent outcome variable and the three groups (CU documentation, CUD documentation, controls) were included as the independent covariates. Using the control group as the reference group, the odds ratios (ORs) of the CU-documented and CUD-documented groups were estimated and statistically tested. A post-hoc analysis was also conducted to estimate and test the OR of CUD documentation compared to CU documentation for each condition controlling for alcohol and tobacco use disorders. ORs were then estimated and tested. A sequentially rejective test procedure [30] was then applied to control for type-one error for multiple comparisons that could emerge due to the large number of tests conducted, and alpha levels were adjusted accordingly at the $p=0.001$ level. All analyses were conducted using SAS 9.4 analytic software. All study procedures and

analyses were approved by the University of California, Los Angeles Institutional Review Board.

Results

Sample characteristics

Table 1 provides an overview of sample characteristics. Overall, the sample was majority male, White, and aged 18–39.

CU and CUD documentation

Of 1,047,463 patients, 4,470 had CUD diagnoses and/or a mention of cannabis in their social history notes; 729 (0.06%) had CUD diagnoses, and 3,741 (0.36%) were in the CU-documented group.

Unadjusted odds of diagnoses

Table 2 includes the unadjusted prevalence of medical diagnoses among patients in the CUD-documented, CU-documented, and matched control groups.

The CUD-documented group had higher unadjusted prevalence of most general medical conditions than the CU-documented and matched controls groups, and CU-documented patients had higher unadjusted prevalence of most conditions when compared to matched controls. The most pronounced differences in unadjusted prevalence were for any mental health disorders (71.1% of the CUD-documented group, 44.4% of the CU-documented group, 21.9% of matched controls), other substance use disorders (44.7% CUD-documented, 13.8% CU-documented, 4.5% matched controls), tobacco use disorder (36.6% CUD-documented, 14.5% CU-documented,

4.9% matched controls), and alcohol use disorder (26.2% CUD, 6.5% CU, 2.6% matched controls). Among diagnoses for conditions known to be associated with cannabis, there was a similar trend, with prevalence being highest among the CUD-documented group, followed by the CU-documented group and matched controls. The largest differences between the groups were in the prevalence of anxiety (60.1% CUD-documented, 36.3% CU-documented, 16.8% matched controls), depression (50.3% CUD-documented, 26.3% CU-documented, 12.4% matched controls) and other substance use disorders.

Adjusted odds of diagnoses

Table 3 shows the adjusted odds that patients with CUD documentation and CU documentation would have diagnoses compared with matched controls and with each other (CUD-documented vs. CU-documented), controlling for alcohol and tobacco diagnoses. For general medical conditions, patients in the CUD-documented group had significantly higher odds of 12 of 13 diagnoses examined when compared to matched controls, with the highest ORs for other substance use disorders (OR=21.44; 95% CI 9.43–48.73), HIV/AIDS (OR=7.88; 95% CI 2.58–24.08), and any mental health disorder (OR=6.99; 95% CI 5.03–9.70). CU-documented patients had higher odds than matched controls of diagnoses for 11 out of 13 diagnoses examined, with the highest odds for other substance use disorders (OR=3.64; 95% CI 2.53–5.25). Compared to CU-documented patients, CUD-documented patients had significantly higher odds of HIV/AIDS (OR=6.70; 95% CI 2.10–21.39), other substance

Table 1 Sample characteristics

	Cannabis Use Disorder (CUD)- Documented (N = 729)	Cannabis Use, (no disorder) (CU)- Documented (N = 3,741)	Matched Controls (4,470)	Total (8,940)
Sex				
Male	556 (77.6%)	2,361 (63.1%)	2,915 (65.2%)	5,832 (65.2%)
Female	173 (23.7%)	1,380 (36.9%)	1,555 (34.8%)	3,108 (34.8%)
Race/Ethnicity				
White	492 (67.5%)	2,406 (64.3%)	2,880 (64.4%)	5,778 (64.6%)
Black	48 (6.6%)	223 (6.0%)	270 (6.0%)	541 (6.1%)
Hispanic	41 (5.6%)	157 (4.2%)	195 (4.4%)	393 (4.4%)
Asian/Pacific Islander	25 (3.4%)	163 (4.4%)	202 (4.5%)	390 (4.4%)
Other/Unknown	123 (16.9%)	791 (21.1%)	922 (20.6%)	1,836 (20.5%)
Age				
18–29	256 (35.1%)	902 (24.1%)	1,158 (25.9%)	2,316 (25.9%)
30–39	157 (21.5%)	969 (25.9%)	1,132 (25.3%)	2,258 (25.3%)
40–49	97 (13.3%)	562 (15.0%)	651 (14.6%)	1,310 (14.7%)
50–59	88 (12.1%)	512 (13.7%)	604 (13.5%)	1,204 (13.5%)
60–69	84 (11.5%)	537 (14.4%)	606 (13.6%)	1,227 (13.7%)
70+	47 (6.4%)	259 (6.9%)	319 (7.1%)	625 (7.0%)

Table 2 Unadjusted prevalence of diagnoses

	Cannabis Use Disorder (CUD) – Documented N = 729	Cannabis Use (no disorder) (CU)-documented N = 3,741	Matched Controls N = 4,470
General Medical Conditions			
Cancer	20.6%	22.1%	15.4%
Diabetes Mellitus	11.8%	7.9%	6.4%
Nervous System Disease	64.5%	52.2%	37.5%
Sleep Disorders	34.7%	23.2%	12.1%
Circulatory System Disease	45.7%	38.7%	29.7%
Respiratory Disease	63.0%	53.9%	43.3%
Digestive System Disease	58.2%	49.1%	34.2%
Liver Disease	12.6%	8.4%	5.2%
Musculoskeletal Disease	66.9%	62.3%	51.0%
HIV/AIDS	3.7%	0.8%	0.8%
Sexually Transmitted Disease	7.1%	3.9%	1.8%
Other Than HIV/AIDS			
Mental Health Disorders	71.1%	44.4%	21.9%
Alcohol Use Disorder	26.2%	6.5%	2.6%
Tobacco Use Disorder	36.6%	14.5%	4.9%
Substance Use Disorder (other than alcohol, cannabis, tobacco)	44.7%	13.8%	4.5%
Conditions Known To Be Associated With Cannabis			
Respiratory Disease	63.0%	53.9%	43.3%
COPD	26.2%	18.7%	13.1%
Cancer	20.6%	22.1%	15.4%
Ischemic Heart Disease	11.8%	7.3%	4.9%
Obstructive Sleep Apnea	7.5%	6.6%	3.5%
Multiple Sclerosis	0.8%	0.7%	0.2%
HIV/AIDS	3.7%	0.8%	0.8%
Tourette Syndrome	0.0%	0.1%	0.0%
Testicular Cancer	0.5%	0.2%	0.3%
Chronic Pain	70.0%	64.7%	52.5%
Schizophrenia/Psychotic Disorder	6.6%	1.7%	0.8%
Depression	50.3%	26.3%	12.4%
Anxiety	60.1%	36.3%	16.8%
Bipolar Disorder	11.1%	4.2%	1.5%
Social Anxiety Disorder	2.9%	0.6%	0.4%
Post-Traumatic Stress Disorder	7.4%	1.8%	0.6%
Alcohol Use Disorder	26.2%	6.5%	2.6%
Substance Use Disorder (other than cannabis, alcohol, tobacco)	44.7%	13.8%	4.5%

use disorders (OR = 5.88; 95% CI 2.43–14.22), and any mental health disorder (OR = 2.48; 95% CI 1.76–3.51).

Among conditions known to be associated with cannabis, CUD-documented patients had higher odds than matched controls for 14 out of 18 conditions, with the highest ORs for other substance use disorders (OR = 21.44; 95% CI 9.43–48.73), social anxiety disorder (OR = 13.03; 95% CI 2.18–77.94), HIV/AIDS

(OR = 7.88; 95% CI 2.58–24.08), post-traumatic stress disorder (OR = 7.44; 95% CI 2.66–22.51), depression (OR = 7.01; 95% CI 4.79–10.27), any mental health disorder (OR = 6.99; 95% CI 5.03–9.70), and bipolar disorder (OR = 6.49; 95% CI 2.90–14.52). CU-documented patients had higher odds of 13 out of 18 conditions compared to matched controls, with the highest ORs for other substance use disorders (OR = 3.64; 95% CI

Table 3 Multivariate conditional logistic models on prevalence of health conditions (controlling for alcohol use disorders and tobacco use) odds ratios (95% confidence interval)

	Cannabis Use Disorder (CUD)- Documented vs Matched Controls	Cannabis Use (no disorder) (CU)-Documented vs Matched Controls	Cannabis Use Disorder (CUD)- Documented vs Cannabis Use (no disorder) (CU) -Documented
General Medical Conditions			
Cancer	2.00 (1.43–2.80)**	1.65 (1.44–1.88)**	1.21 (0.85–1.73)
Diabetes Mellitus	1.95 (1.26–3.02)	1.23 (1.01–1.50)	1.58 (0.99–2.53)
Nervous System Disease	2.67 (2.06–3.47)**	2.01 (1.81–2.24)**	1.33 (1.01–1.75)
Sleep Disorders	3.70 (2.69–5.08)**	2.38 (2.07–2.74)**	1.55 (1.11–2.17)
Circulatory System Disease	2.04 (1.54–2.69)**	1.69 (1.50–1.90)**	1.20 (0.90–1.62)
Respiratory Disease	1.58 (1.24–2.00)*	1.65 (1.49–1.83)**	0.95 (0.74–1.23)
Digestive System Disease	2.08 (1.62–2.67)**	2.03 (1.82–2.25)**	1.03 (0.79–1.34)
Liver Disease	1.86 (1.20–2.90)*	1.68 (1.37–2.06)**	1.11 (0.69–1.78)
Musculoskeletal Disease	1.76 (1.36–2.26)**	1.67 (1.51–1.85)**	1.05 (0.80–1.37)
HIV/AIDS	7.88 (2.58–24.08)*	1.18 (0.69–2.00)	6.70 (2.10–21.39)**
Sexually Transmitted Disease Other Than HIV/AIDS	3.39 (1.81–6.36)**	2.28 (1.68–3.08)**	1.49 (0.75–2.94)
Mental Health Disorders	6.99 (5.03–9.70)**	2.81 (2.51–3.15)**	2.48 (1.76–3.51)**
Substance Use Disorder (other than alcohol, cannabis, tobacco)	21.44 (9.43–48.73)**	3.64 (2.53–5.25)**	5.88 (2.43–14.22)**
Conditions Known To Be Associated With Cannabis			
Respiratory Disease	1.58 (1.24–2.00)*	1.69 (1.05–2.73)	0.95 (0.74–1.23)
COPD	1.67 (1.23–2.27)	1.49 (1.30–1.71)*	1.12 (0.81–1.55)
Chronic Obstructive Pulmonary Disease	2.51 (1.47–4.30)*	1.57 (1.26–1.95)**	1.61 (0.90–2.85)
Cancer	2.00 (1.43–2.80)**	1.65 (1.44–1.88)*	1.21 (0.85–1.73)
Ischemic Heart Disease	2.51 (1.47–4.30)*	1.57 (1.26–1.95)**	1.61 (0.90–2.85)
Obstructive Sleep Apnea	2.11 (1.27–3.50)*	2.07 (1.64–2.62)**	1.02 (0.59–1.75)
Multiple Sclerosis	6.09 (0.64–57.44)	3.14 (1.38–7.12)*	1.94 (0.20–18.81)
HIV-AIDS	7.88 (2.58–24.08)*	2.28 (1.68–3.08)**	6.70 (2.10–21.39)*
Tourette Syndrome	0 (0.00–1.00)	2.00 (0.18–22.06)	0 (0.00–1.00)
Testicular Cancer	2.11 (0.25–18.05)	0.70 (0.27–1.86)	3.00 (0.30–29.75)
Chronic Pain	1.85 (1.44–2.38)**	1.74 (1.57–1.93)**	1.06 (0.81–1.38)
Schizophrenia/Psychotic Disorder	5.98 (2.23–16.03)*	1.69 (1.05–2.73)	3.53 (1.18–10.53)
Depression	7.01 (4.79–10.27)**	2.46 (2.15–2.81)**	2.85 (1.90–4.26)**

Table 3 (continued)

	Cannabis Use Disorder (CUD)- Documented vs Matched Controls	Cannabis Use (no disorder) (CU)-Documented vs Matched Controls	Cannabis Use Disorder (CUD)- Documented vs Cannabis Use (no disorder) (CU) -Documented
Anxiety	5.99 (4.37–8.21)**	2.74 (2.43–3.08)**	2.19 (1.57–3.05)**
Bipolar Disorder	6.49 (2.90–14.52)**	2.54 (1.84–3.51)**	2.56 (1.07–6.09)
Social Anxiety Disorder	13.03 (2.18–77.94)*	1.64 (0.85–3.17)	7.93 (1.24–50.59)
Post-Traumatic Stress Disorder	7.74 (2.66–22.51)*	3.41 (1.99–5.83)**	2.27 (0.73–7.13)
Substance Use Disorder (other than alcohol, cannabis, tobacco)	21.44 (9.43–48.73)**	3.64 (2.53–5.25)**	5.88 (2.43–14.22)*

* $P < .01$ ** $P < .001$

2.53–5.25) and post-traumatic stress disorder (OR = 3.41; 95% CI 2.53–5.25). CUD-documented patients were significantly more likely than CU-documented patients to have HIV/AIDS (OR = 6.70; 95% CI 2.10–21.39), other substance use disorder (OR = 5.88; 95% CI 2.42–14.22), depression (OR = 2.85; 95% CI 1.90–4.26), and anxiety (OR = 2.19; 95% CI 1.57–3.05).

Discussion

Key results

Under one percent of the sample in this study had documentation of CU or CUD in their EHR, compared to studies of EHR data from Washington State, which found EHR-documented cannabis use rates between 15 and 22% [16, 17]. Some of this difference may be due to higher levels of adult CU, frequent cannabis use, and CUD in states like Washington that allow non-medical marijuana use [23]. Also, the sample in this study was mostly commercially insured and of relatively high income, so these factors may account for the differences from the Washington State samples. However, the rate of CU and CUD documentation in EHRs in this study was still surprisingly low. According to the U.S. National Survey on Drug Use and Health, 16.4% of Californians over age 12 reported past-year CU between 2014 and 2017, and 2.0% of this population had a CUD [31]. Part of the reason for these discrepancies could be in the methods used to identify CU and CUD among the patient populations. In the Washington State studies, all patients completed a cannabis screening at a primary care visit, whereas in this study, patients were not routinely screened. The large gap between rates of CU and CUD in California population surveys and the frequency of CU and CUD documentation in EHRs in this study could be indicators of how cannabis use can go undetected during primary care visits in the absence of systematic screening [32]. California healthcare providers may now begin screening for CU

and CUD more since the U.S. Preventive Services Task Force has recommended drug use screening for adults in primary care [33], and this may lead to better identification of cannabis use in medical settings. This finding also underscores the importance of having healthcare providers in other states and countries—both those with and without legalized marijuana—systematically screen patients for CUD and cannabis use.

Study findings also shed light on the association between CUD documentation, CU documentation, and health among primary care patients in medical marijuana jurisdictions, showing that cannabis use is associated with many physical health conditions. CUD-documented patients in this study were over seven times as likely as matched controls to have HIV/AIDS diagnoses, three times as likely to have sleep disorder diagnoses, and twice as likely to have nervous system disease, digestive system disease, circulatory system disease, ischemic heart disease, fibromyalgia, and sleep apnea diagnoses. CU-documented patients also had increased odds for most of these conditions, though not as much as CUD-documented patients. Elevated rates of medical problems could result from direct physical effects of regular cannabis use and associated behaviors, and the fact that individuals with substance use disorders (including cannabis use disorder) are less likely than others to access and receive quality health care [10, 34–36]. Conversely, it is possible that some of this association is due to people with medical conditions using cannabis to manage or alleviate their symptoms [13, 37–39]. These findings indicate a stronger association between cannabis use and medical diagnoses than that found by Matson et al. [17] in their study of EHR data from Washington State. These differences may be attributable to the fact that unlike Washington State, California was a medical marijuana state at the time of this study, but had not yet legalized cannabis

use generally. California patients may have been less likely to report their cannabis use due to fear of legal or social consequences for disclosing their substance use, leading providers to only identify CU or CUD in cases where it was discernible from patient presentation. Furthermore, unlike in the Matson et al. study, patients in this sample were not identified by universal screening. Consequently, it is possible that patients in this sample only had their cannabis use noted in their EHR if it emerged as a topic in the course of their primary care encounter, meaning that their cannabis use and its consequences may have been particularly severe or salient. By having respectful, nonjudgmental, and balanced discussions about the pros and cons of cannabis use with patients, medical providers may be able to decrease patient reluctance to disclose and discuss their cannabis use [5, 40]. Further research can help determine the degree to which the policy context and/or different methods for identifying patients who used cannabis may have accounted for the different findings reported here and those reported in other EHR studies.

When compared to physical health diagnoses, the odds of CU-documented and CUD-documented patients having behavioral health diagnoses relative to matched controls were particularly high. CUD-documented patients were nearly six times as likely as matched controls to have diagnoses of schizophrenia/psychotic disorders, over seven times as likely to have a depression diagnoses, over six times as likely to have a bipolar disorder diagnosis, and six times as likely to have anxiety diagnoses. For CU-documented patients, odds of these conditions were also elevated, but not nearly as much as for CUD-documented patients. Moreover, CUD-documented patients were over three times as likely as CU patients to have schizophrenia/psychotic disorders, and over twice as likely to have depression or anxiety diagnoses. These findings support the extensive body of research demonstrating a correlation between cannabis use and mental health problems [8, 11, 16, 41–44] and the association between cannabis use documentation and the presence of psychiatric diagnoses in EHRs [15, 17]. They also underscore the importance of screening and assessment for co-occurring mental health disorders among people who use cannabis or have cannabis use disorders, and ensuring that they receive evidence-based psychosocial and pharmacological interventions as needed [45–48]. Many of the behavioral interventions that have shown efficacy in addressing problematic cannabis use—such as motivational enhancement therapy, cognitive behavioral therapy, and contingency management—are also effective for treating other behavioral disorders, and could help improve the overall behavioral health of primary care patients with CUD [46, 47, 49].

Odds of other substance use disorders were also higher among the CUD-documented group when compared to matched controls, as they had over 21 times the risk of having other substance use disorder diagnoses. As with mental health diagnoses, the CU-documented group was also at elevated risk for substance use disorder diagnoses, but not nearly as much as the CUD-documented group. Compared to CU-documented patients, CUD-documented patients were over five times as likely to have another substance use disorder diagnosis. These findings align with other research demonstrating associations between cannabis use, increased use of other substances, and increased risk for other substance use disorders [8, 16, 17, 38, 50, 51].

The significantly increased odds of HIV/AIDS diagnoses among CUD-documented patients—but not among CU-documented patients—is also notable. There is limited evidence showing cannabis can be effective for increasing appetite and decreasing weight loss associated with HIV/AIDS [13], though evidence on its long-term safety and impact on long-term AIDS-related morbidity and mortality is limited [52]. However, some research has found cannabis dependence is associated with lower adherence to antiretroviral therapy and increased HIV symptoms and medication side effects [53], so the high prevalence of HIV/AIDS among the CUD-documented group in this study is concerning. This finding aligns with previous research showing relatively high levels of frequent cannabis use among people living with HIV [54], and highlights the need to detect CUD among this population and provide them with effective counseling and support to help them manage their cannabis use [55].

Limitations

Several key limitations should be noted. First, the study drew data from one university health system, and may not be generalizable to other primary care populations in other regions or countries. Second, measures of CUD and CU documentation were extracted from EHRs that did not have specific questions prompting provider to elicit data concerning cannabis use. This could account for the low rates of CUD and CU documentation in the sample, and it is possible that CUD and CU were only noted either when patients mentioned cannabis, or when providers detected issues that prompted them to ask about substance use. Consequently, there is a good possibility that only patients with outward signs of cannabis use or who self-disclosed cannabis use were detected, and these patients may use cannabis more frequently or heavily than most patients who use the drug. Other studies have documented under-diagnosis of CUD in medical records in the absence of routine screening and assessments [32]. Study findings can be interpreted as

supporting the associations between CUD and CU at a threshold level that merits documentation in medical records, and should be interpreted within this context.

Third, since the dataset only allowed for identification of CUD and CU documentation, the study does not include information concerning frequency of use, duration of use, quantities used, types of products used, or potencies of cannabis products consumed. This information would be needed in order to come to more precise conclusions concerning the relationship between cannabis and medical conditions. Despite these limitations, the medical records data used have several advantages, including the large and diverse population, standardized medical codes and detailed case notes, and accumulation of relevant diagnostic data over multiple visits.

Conclusions

This study highlights the relationship between cannabis use and cannabis use disorder documentation with other medical, mental health, and other substance use disorders in states where medical marijuana is legal. Given the strong associations of cannabis use and cannabis use disorder documentation with health problems—particularly those related to mental health, substance use, and HIV—it is important for healthcare providers in such jurisdictions to be prepared to identify cannabis use and cannabis use disorders, and address these comorbidities among these patients. Study findings also suggest the need for future research on optimal strategies for initiating discussion of cannabis use and its potential benefits and adverse effects with primary care patients, particularly those already known to have medical and behavioral health conditions.

Appendix

ICD-10 codes used to identify medical and behavioral health conditions

Cancer: C00-26, C30-41, C43-58, C60-76, D00-09, D37-49

Diabetes Mellitus: E08-E13

Nervous System Disease: G00-G99

Sleep Disorders: F10.182, F10.282, F11.182, F11.282, F11.982, F13.182, F13.282, F13.982, F14.182, F14.282, F14.982, F15.182, F15.282, F15.982, F19.182, F19.282, F19.982, F51, G47

Circulatory System Disease: I00-I99

Respiratory Disease: J00-J99

Digestive System Disease: K00-K98

Liver Disease: K70-77

Musculoskeletal Disease: M00-M99

HIV/AIDS B20, Z21

Sexually Transmitted Diseases other than HIV/AIDS: A50-64

Mental Health Disorders: F06, F20-48

Alcohol Use Disorder: F10

Tobacco Use Disorder: F17

Substance Use Disorder other than alcohol, cannabis, tobacco: F11, F13-16, F18-19

Chronic Obstructive Pulmonary Disease: J40-47

Ischemic Heart Disease: I20-25

Obstructive Sleep Apnea: G47.33

Multiple Sclerosis: G35

Tourette Syndrome: F95.2

Testicular Cancer: C62

Chronic Pain: F45.4, G43, G44.2, G89, M00-99

Schizophrenia/Psychotic Disorder: F06.0, F06.2, F20-29

Depression: F06.31-32, F32, F33, F34.1

Anxiety: F06.4, F40-48

Bipolar Disorder: F31

Social Anxiety Disorder: F40.10

Post-Traumatic Stress Disorder: F43.10, F43.12

Abbreviations

EHR: Electronic Health Record; CUD: Cannabis Use Disorder; CU: Cannabis Use; ICD-10: International Classification of Diseases, Tenth Revision; HIV/AIDS: Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; COPD: Chronic Obstructive Pulmonary Disease; OR: Odds Ratio; US: United States; CI: Confidence Interval.

Acknowledgements

The authors acknowledge the assistance of (names blinded for review) from the (institution name blinded for review) for their assistance with this project.

Authors' contributions

HP conceptualized the study, co-facilitated analyses, interpreted results, and drafted the manuscript. DH led statistical analyses. DB led the process of procuring data used for analysis. DB, LM, CG, DU, BB, and AB assisted HP in conceptualizing the study, assisted with data interpretation, and provided substantive input during the manuscript preparation and review processes. The author(s) read and approved the final manuscript.

Funding

This research was supported by U.S. Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translational Sciences, Grant UL1TR001881.

Availability of data and materials

Data for this study came from medical system EHRs and is not publicly available. These data are only available to clinicians and researchers from the University of California, Los Angeles.

Declarations

Ethics approval and consent to participate

The study had ethical approval from the University of California, Los Angeles Institutional Review Board. Informed consent was waived for this study since it used pre-existing data stored in a large database, and all data were deidentified prior to analysis.

Consent for publication

The University of California, Los Angeles Institutional Review Board approved the study and provided permission to publish. Consent from patients was

not obtained since the study used deidentified data from a large, pre-existing dataset.

Competing interests

The authors have no competing interests to report.

Author details

¹Department of Psychiatry and Biobehavioral Sciences, University of California, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA.

²Division of General Internal Medicine, Department of Medicine, University of California, Los Angeles, USA. ³Clinical and Translational Science Institute, University of California, Los Angeles, USA. ⁴School of Government & Public Policy, University of Arizona, Tucson, USA.

Accepted: 25 April 2022

Published online: 08 May 2022

References

1. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, Degenhardt L. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. *Addiction*. 2018;113(10):1905–26.
2. Hasin DS. US epidemiology of cannabis use and associated problems. *Neuropsychopharmacol*. 2018;43(1):195–212.
3. Keyhani S, Steigerwald S, Ishida J, Vali M, Cerdá M, Hasin D, Cohen BE. Risks and benefits of marijuana use: a national survey of US adults. *Ann Int Med*. 2018;169(5):282–90.
4. Lau N, Gerson M, Korenstein D, Keyhani S. Internet claims on the health benefits of cannabis use. *J Gen Int Med*. 2021;36(11):3611–4.
5. Strouse TB. Cannabinoids in medical practice. *Altern Complem Ther*. 2016;22(2):59–63.
6. Hall W, Stjepanović D, Caulkins J, Lynskey M, Leung J, Campbell G, Degenhardt L. (2019). Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. *Lancet*. 2019;394(10208):1580–90.
7. Hall W, Lynskey M. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. *World Psych*. 2020;19(2):179–86.
8. Kim JH, Weinberger AH, Zhu J, Barrington-Trimis J, Wyka K, Goodwin RD. Impact of state-level cannabis legalization on poly use of alcohol and cannabis in the United States, 2004–2017. *Drug Alc Dep*. 2021;218:108364.
9. Goldenberg M, Reid MW, IsHak WW, Danovitch I. The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. *Drug Alc Dep*. 2017;174:80–90.
10. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet*. 2009;374(9698):1383–91.
11. Hanna RC, Perez JM, Ghose S. Cannabis and development of dual diagnoses: a literature review. *Am J Drug Alc Ab*. 2017;43(4):442–55.
12. Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Howes OD. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. *Lancet Psych*. 2020;7(4):344–53.
13. National Academies of Sciences Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington: The National Academies Press; 2017.
14. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *NEJM*. 2014;370(23):2219–27.
15. Campbell A, Bailey SR, Hoffman KA, Ponce-Terashima J, Fankhauser K, Marino M, McCarty D. Associations between psychiatric disorders and cannabis-related disorders documented in electronic health records. *J Psych Drug*. 2020;52(3):228–36.
16. Lapham GT, Lee AK, Caldeiro RM, Glass JE, Carrell DS, Richards JE, Bradley KA. Prevalence of behavioral health conditions across frequency of cannabis use among adult primary care patients in Washington State. *J Gen Int Med*. 2018;33(11):1833–5.
17. Matson TE, Carrell DS, Bobb JF, Cronkite DJ, Oliver MM, Luce C, Lapham GT. Prevalence of medical cannabis use and associated health conditions documented in electronic health records among primary care patients in Washington State. *JAMA Net Op*. 2021;4(5):e219375–e219375.
18. Davenport S. Price and product variation in Washington's recreational cannabis market. *Int J Drug Pol*. 2019;91:102547.
19. Mahamad S, Wadsworth E, Rynard V, Goodman S, Hammond D. Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalisation. *Drug Alc Rev*. 2020;39(4):337–46.
20. Sevigny EL, Pacula RL, Heaton P. The effects of medical marijuana laws on potency. *Int J Drug Pol*. 2014;25(2):308–19.
21. Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. *Addiction*. 2017;112(12):2167–77.
22. Smart R, Pacula RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: findings from state policy evaluations. *Am J Drug Alc Ab*. 2019;45(6):644–63.
23. Cerdá M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, Martins SS. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. *JAMA Psych*. 2020;77(2):165–71.
24. National Conference of State Legislatures. State Medical Marijuana Laws. Retrieved from <https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#3> May 21, 2021.
25. United Kingdom Statutory Instruments No. 1055: The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England Wales and Scotland) Regulations 2018. Retrieved from <https://www.legislation.gov.uk/ukksi/2018/1055/made> August 26, 2021.
26. Arnold JC, Nation T, McGregor IS. Prescribing medical cannabis. *Austral Prescr*. 2020;43(5):152–9.
27. Bifulco M, Pisanti S. Medicinal use of cannabis in Europe. *EMBO Rep*. 2015;116(2):130–2.
28. Corda A, Cortes E, Arriagada DP. Summary of the CEDD Regional Report: Cannabis in Latin America – The Green Wave and Challenges for Regulation. Bogota: Colectivo de Estudios Drogas y Derecho; 2019.
29. Keyhani S, Vali M, Cohen B, Woodbridge A, Arenson M, Eikhani E, et al. A search algorithm for identifying likely users and non-users of marijuana from the free text of the electronic medical record. *PLoS ONE*. 2018;13(3):e0193706.
30. Rom DM. A sequentially rejective test procedure based on a modified Bonferroni inequality. *Biometrika*. 1990;77(3):663–5.
31. United States Substance Abuse and Mental Health Services Administration. Behavioral Health Barometer: California, Volume 5: Indicators as measured through the 2017 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services. HHS Publication No. SMA-19-Baro-17-CA. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2019.
32. Bonn-Miller MO, Bucossi MM, Trafton JA. The underdiagnosis of cannabis use disorders and other Axis-I disorders among military veterans within VHA. *Mil Med*. 2012;177(7):786–8.
33. U.S. Preventive Services Task Force. Screening for unhealthy drug use; U.S. preventive services task force recommendation statement. *JAMA*. 2020;323(22):2301–9.
34. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? *Addiction*. 2015;110(1):19–35.
35. van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Inequalities in healthcare provision for individuals with substance use disorders: perspectives from healthcare professionals and clients. *J Subs Ab Treat*. 2016;21(2):133–40.
36. Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. *Brit J Psych*. 2009;194(6):491–9.
37. Bohnert KM, Bonar EE, Arnedt JT, Conroy DA, Walton MA, Ilgen MA. Utility of the comprehensive marijuana motives questionnaire among medical cannabis patients. *Addict Behav*. 2018;76:139–44.
38. Grella CE, Rodriguez L, Kim T. Patterns of medical marijuana use among individuals sampled from medical marijuana dispensaries in Los Angeles. *J Psychoact Drug*. 2014;46(4):263–72.
39. Sarvet AL, Wall MM, Keyes KM, Olfson M, Cerdá M, Hasin DS. Self-medication of mood and anxiety disorders with marijuana: Higher in states with medical marijuana laws. *Drug Alc Dep*. 2018;186:10–5.
40. Colorado Office of Behavioral Health. Marijuana Clinical Guidance: Information to Guide Work with Adolescents and Adults 2017. Retrieved from.

<https://www.masbirt.org/sites/www.masbirt.org/files/Marijuana/Marijuana-Clinical-Guidance-for-posting.pdf>. Accessed 28 Sept 2021.

41. Dierker L, Selya A, Lanza S, Li R, Rose J. Depression and marijuana use disorder symptoms among current marijuana users. *Addict Behav.* 2018;76:161–8.
42. Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, van der Ven E. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psych.* 2019;6(5):427–36.
43. Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. *World Psych.* 2008;7(2):68.
44. Reece AS, Hulse GK. Co-occurrence across time and space of drug-and cannabinoid-exposure and adverse mental health outcomes in the National Survey of Drug Use and Health: combined geotemporospatial and causal inference analysis. *BMC Pub Health.* 2020;20(1):1–15.
45. Akerman SC, Brunette MF, Noordsy DL, Green AI. Pharmacotherapy of co-occurring schizophrenia and substance use disorders. *Curr Addict Rep.* 2014;1(4):251–60.
46. Bradizza CM, Stasiewicz PR, Dermen KH. Behavioral interventions for individuals dually diagnosed with a severe mental illness and a substance use disorder. *Curr Addict Rep.* 2014;1(4):243–50.
47. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. *Harv Rev Psych.* 2009;17(1):24–34.
48. United States Substance Abuse and Mental Health Services Administration. Substance Use Disorder Treatment for People With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series, No. 42. SAMHSA Publication No. PEP20–02–01–004. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2020.
49. Danovitch I, Gorelick DA. The treatment of cannabis use disorder. In I. Danovitch & LJ Mooney (Eds) *The Assessment and Treatment of Addiction: Best Practices and New Frontiers*. Elsevier: St. Louis, MO: 2019:105–121.
50. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. *Addiction.* 2006;101(4):556–69.
51. Gorfinkel LR, Stohl M, Greenstein E, Aharonovich E, Olfson M, Hasin D. Is Cannabis being used as a substitute for non-medical opioids by adults with problem substance use in the United States? a within-person analysis. *Addiction.* 2021;116(5):1113–21.
52. Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Coch Data Syst Rev.* 2–13:4
53. Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. *J Behav Med.* 2014;37(1):1–10.
54. Pacek LR, Towe SL, Hobkirk AL, Nash D, Goodwin RD. Frequency of cannabis use and medical cannabis use among persons living with HIV in the United States: findings from a nationally representative sample. *AIDS Educ Prev.* 2018;30(2):169–81.
55. Hartzler B, Carlini BH, Newville H, Crane HM, Eron JJ, Geng EH, Donovan DM. Identifying HIV care enrollees at-risk for cannabis use disorder. *AIDS Care.* 2017;29(7):846–50.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

